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CLINICAL UPDATE
CHARLES SCERRI
The National Institute of Clinical Excellence (NICE) has lately overturned its 
decision to restrict the use of acetycholinesterase inhibitors and memantine 
in patients diagnosed with Alzheimer’s disease (AD). It is estimated that such 
a policy U-turn will offer access to a significant number of individuals who 
were previously denied these medications. This short article will focus on 
the latest developments and recommendations by NICE on the use of these 
pharmacological agents in the managment of AD.
NICE 2011 recommendations 
on the management of Alzheimer’s disease 
by acetylcholinesterase inhibitors & memantine
AD is the most common form of dementia accounting for about 
50-70% of the cases. It is the most 
common neurodegenerative disorder in 
the elderly with a prevalence rate that 
increases exponentially from 2-3% in 
the general population at the age of 
65 years to that exceeding 40% after 
the age of 85 years. Given the trend 
towards an increase in the elderly 
population worldwide, the prevalence 
of AD is expected to double in the next 
forty years. In Malta, it is estimated that 
currently the number of individuals with 
dementia almost reaches 4,500. This 
figure is expected to almost double, 
reaching 2% of the Maltese population 
by the year 20501. In addition to the 
huge costs involved in the medical 
management of AD, its psychosocial 
burden on caregivers and society in 
general is enormous.
Pathologically, AD is characterised 
by the presence of amyloid plaques 
and neurofibrillary tangles in the 
brain coupled with significant loss of 
cholinergic tracts in areas associated 
with learning and memory. The 
disease is a multistage process initially 
characterised by a decline in short-
term memory, faulty judgment and 
personality changes. At later stages, 
memory decline worsens and activities 
of daily living and communication 
skills become gradually impaired. In 
the final stages, the patient becomes 
mute, withdrawn, incontinent and 
unable to walk with the consequence 




(AChEIs) were the first pharmacological 
agents for the management of AD 
approved by the relevant health 
authorities. Locally, three AChEIs 
are clinically available: donepezil, 
rivastigmine and galantamine. Their 
major therapeutic effect is reported to 
be their ability to maintain cognitive 
function compared to placebo over 
a three year period or less2,3. These 
drugs are particularly useful in mild to 
moderate stages of AD. A later addition 
to the list of drugs recommended for 
use in AD patients was memantine, 
a compound that appears to block 
pathologic neural toxicity associated 
with prolonged glutamate release4. In 
randomised clinical trials, this drug 
demonstrated the ability to delay 
cognitive decline and is recommended 
for the use in moderate to severe AD.
In  2006, NICE advised that 
donepezil, rivastigmine and 
galantamine should only be used to 
treat moderate stage AD and that 
memantine should be reserved for 
clinical studies involving individuals 
with moderately severe to severe AD. 
This meant that in the UK, these drugs 
could not be used to treat the disease 
in its mild form via the NHS. As expected, 
these restrictions were met with strong 
resistance and various organisations 
across the UK voiced their concerns 
about this approach, highlighting the 
need for NICE to reassess its views. 
These included Alzheimer’s Society, Age 
Concern, Counsel and Care, Dementia 
Care Trust, the Royal College of Nursing, 
the Royal College of Psychiatrists and 
the British Geriatrics Society.
Even Alzheimer’s Europe called for 
NICE to revise its recommendations and 
allow patients at all stages of the disease 
to have access to the various drug 
treatments.
The discussion on 
the use of such drugs 
continued and after 
considering evidence 
from a number of recent 
scientific publications on 
the cost-effectiveness 
of these agents as well 
as feedback from drug 
manufacturers, professional 
and patients groups and 
other consultees, NICE reversed its 
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Invitation to participate in a survey
As part of an MSc in Public 
Health Medicine, one of our 
members is carrying out a study on 
Medication Errors. You are being 
invited to participate in a short, 
completely anonymous survey 
which may be found on http://www.
thesynapse.net/articles/viewarticle.
asp?artid=13424. Your cooperation 
is greatly appreciated. 
Since the beginning of 2010, TheSynapse 
magazine front page has featured a photograph 
of Maltese plants which were renowned for their 
medicinal properties. We have been lucky enough 
to be given permission to use these pictures by 
none other than Guido Bonett who holds various 
prestigious nature photography awards. 
We are pleased to announce the launch 
of a Photography competition for members of 
TheSynapse where we invite submissions from 
all members of the medical professions, including 
students. The best six photographs will be used 
for the front page of TheSynapse magazine 
for 2012. Obviously the photographer will be 
acknowledged. The theme of the photography 
competition will be Malta and Medicine and you 
can submit any photo that fits into this broad 
category. The photographs will be uploaded on 
to a specific website and anyone can vote for the 
best picture. Votes from the website will account 
for 50% of total votes whereas the other 50% 
will be from a panel of expert and well renowned 
local photographers who will act as judges. 
Details of the website address and prizes will 
be announced in the coming weeks. The Photo 
Contest Rules, Terms and Conditions may be 
acessed on www.thesynapse.net
Victor Grech’s piece (“Lydgate, 
brain drain and the Maltese medical 
profession”, The Synapse Magazine, 
03/11) touches on a difficult subject 
indeed.  I am not (as stated) a retired 
doctor, but am now a freelance 
surgical pathologist and teacher of 
disease mechanisms who chose 
to terminate employment by the 
state monopolies for health services 
and medical teaching.   Some 
of my reasons for resigning my 
University position, and to turn 
down an offered post-age-61 
NHS contract, had to do with 
the content of Professor Grech’s 
feature.  I was tired of working far 
longer hours than some colleagues 
in other specialities in both the 
NHS and medical school set-
ups.  I did wonder whether paying 
consultants, and senior university 
teachers, a fee per item of service, 
rather than a straight salary, would 
quickly dispose of waiting lists and 
university teachers’ absenteeism. 
The MAM’s main concern has 
been, for several decades, the 
maintenance of the “half-day-
hospital” status quo (no out-patient 
sessions in the afternoons, etc) 
because private practice time is more 
highly priced than salary and pension 
rates by top-earning clinicians, who 
regard “ownership” of teaching hospital 
beds more remunerative.  MAM has 
never expressed any concern about 
colleagues who have worked significant 
number of years for both the British 
and Maltese NHS and then discover, 
at age 61, that a good part (if not all) of 
their Maltese 2/3 pension is withheld, 
because current Maltese social security 
law does not permit them to enjoy 
the two pensions they’ve contributed 
to.   An important omission in Victor 
Grech’s piece is the recognition of 
Malta’s small size problem.  Some 
might be patting themselves on the 
back for churning out around 80 new 
doctors annually, for local postgraduate 
training programmes, and for the 
expansion of consultant posts (but 
still half-day-hospital work pattern).  
The UK “release valve” for our doctor 
over-production might gradually close 
(a population of only 400,000 would 
not need 80 new doctors annually).  A 
consequence of that might be unethical 
attempts at “expanding the private 
market” by punishing unwitting patients 
with unnecessary expensive tests and 
procedures for body malfunctions 
which could otherwise be corrected 
by nutritional and lifestyle changes (if 
only the medical school had taught 
them how to do it).  Another problem 
related to our small size is perhaps 
best illustrated by a friend of mine 
who paid to have some ceramic-
work lessons and was told that not 
all the professional skill secrets of 
the trade were available for sale.  I’m 
sure readers would understand the 
consequences of similar attitudes 
in medical postgraduate education.  
Another problem exacerbated by 
our small size and private practice is 
possible obstruction to repatriation of 
highly skilled doctors, or obstructions 
to their promotion to senior positions 
once they return.  Readers will forgive 
me for not having the time to find and 
quote the precise references, but they 
might remember that lawyer Giovanni 
Bonello contributed a few articles to 
the Maltese Medical Journal, one of 
which highlighted how local doctors 
prevented other Maltese doctors from 
returning after training overseas at the 
time of the Crusaders, and another 
one how some of them acquired land 
as a gift from the Grandmaster.  
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Doctor Wanted
Ethnically Maltese speaking General 
Medical Practitioner required to work 
in Copernicus Clinic, Keilor Downs, 
Melbourne Australia, in a modern 
computerised  clinic with nurse and 
auxiliary staff. Will eventually replace 
retiring doctor. On-site lodging 
available. Please call +61416296337 or 
email vsammut@copernicusclinic.com.
Attention Consultants and other 
Medical Specialists
 Clinic space available. No rental 
fee. For more information please call 
79060903. 
If you want to advertise your 
conference free of charge simply 
click on http://www.thesynapse.
net/events/list.asp 
6th Biennial Primary Health Department Conference 2011 to be held on 11/10/2011 
Malta’s Primary Health Department wishes to invite prospective delegates to submit abstracts for the 6th 
Biennial Primary Health Department Conference 2011 “Primary Health in Malta - from the Cradle to the Grave?” 
that will take place at the Westin Dragonara Resort, St Julian’s, on Tuesday, 11th October, 2011. The Organising 
Committee intends to apply for CME / CPD points to be awarded to participants. For further details please click 
http://www.thesynapse.net/events/view.asp?eventID=131 for the call for abstracts which closes on the 29th July 
2011.  Kindly book this date in your dairy!
MEMbErs’ COrNEr
decision through the publication of a technology appraisal 
report in March 20115. Recommendations set out in this 
guidance report include:
• The three acetylcholinesterase inhibitors (AChEIs) donepezil, 
galantamine and rivastigmine are recommended as options 
for managing mild to moderate AD;
• Memantine is recommended as an option for managing 
AD for people with moderate or severe AD;
• Treatment should be recommended only by specialists 
and when considered to have a worthwhile effect on the 
cognitive, functional and behavioural symptoms;
• Patients should be reviewed regularly and treatment 
adjusted depending on the symptoms as reviewed 
by a specilised team. The carer’s view should also be 
consulted at follow-up;
• Although treatment with AChEIs should be started with 
the drug with the lower acquisition cost, an alternative 
AChEI could be prescribed if found to be appropriate 
based on adverse event profile, patient compliance, 
medical comorbidity and dosing regimens;
• Communication difficulties and sensory or learning 
disabilities should be taken into consideration when 
assessment scales are used to determine the severity of 
AD;
• Healthcare professionals should not rely solely on 
cognition scores in circumstances in which it would be 
inappropriate to do so, such as in sensory impairments, 
communication difficulties or level of education.
In conclusion, these latest recommendations by 
NICE are in line with accumulating evidence showing 
that these drugs enhance activities of daily living, reduce 
behavioural disturbances, slow cognitive impairment and 
decrease caregiver stress thus delaying institutionilisation. 
Unfortunately in Malta, AD is not among the list of chronic 
disorders on the Fifth Schedule of the Social Security 
Act and therefore these drugs are only available in the 
community as an out-of-pocket expense. It is hoped 
that the local health authorties follow the example of the 
majority of countries in the European Union and reimburse 
AD drugs to all those individuals suffering from this 
debiliating disease.  
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